Phathom Pharmaceuticals, Inc. PHAT
Set alert
At close · Oct 30
After hours · Oct 30, 6:36 PM ET
- YTD
- -65.40%
- 1 year
- -56.87%
- Open
- 6.32
- Prev close
- 6.22
- Mkt cap
- 466.61M
- Vol
- 1.62M
- Avg vol
- 1.46M
- EPS
- -1.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.59
- High
- 6.32
- Forward P/E
- 7.60
- Beta
- 0.61
- Short ratio
- 9.36
- Inst. own
- 83.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.63
- 200-d avg
- 12.45
- 1y target
- 23.70
5D chart
Signals (78)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| RSI: Overbought | Oct 28, 3:05 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:25 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
2 days ago marketbeat.com
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company…
3 days ago seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
3 days ago zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.15 per share a year…
3 days ago benzinga.com
Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
-
3 days ago benzinga.com
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $310.000 million-$325.000 million to $310.000 million-$325.000 million vs $314.842 million estimate.
-
3 days ago benzinga.com
Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 126.67 percent increase over losses…
3 days ago globenewswire.com
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs.
6 days ago globenewswire.com
Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
1 week ago globenewswire.com
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
1 week ago globenewswire.com
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT
-
2 weeks ago benzinga.com
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;
New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at…
3 weeks ago globenewswire.com
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in…
-
1 month ago benzinga.com
Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results…
1 month ago globenewswire.com
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results…
1 month ago defenseworld.net
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume…
1 month ago gurufocus.com
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
1 month ago businesswire.com
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
2 months ago globenewswire.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for…
-
2 months ago benzinga.com
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
2 months ago globenewswire.com
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the…
3 months ago businesswire.com
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its…
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
3 months ago prnewswire.com
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
/PRNewswire/ -- Investors in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) were told the Company's full-year revenue guidance was intact -- then watched that
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
3 months ago seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
3 months ago prnewswire.com
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT…
-
3 months ago benzinga.com
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.
3 months ago marketbeat.com
Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first…
3 months ago zacks.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.79 per share a year ago.
-
3 months ago benzinga.com
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of…
-
3 months ago benzinga.com
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
-
3 months ago benzinga.com
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over…
-
4 months ago benzinga.com
Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
7 months ago benzinga.com
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.
-
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
9 months ago benzinga.com
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 months ago benzinga.com
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Earnings Scheduled For October 30, 2025
Earnings Scheduled For October 30, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 year ago benzinga.com
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
1 year ago benzinga.com
Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.